MCID: TNG003
MIFTS: 55

Tongue Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tongue Cancer

MalaCards integrated aliases for Tongue Cancer:

Name: Tongue Cancer 12 52 54 15
Tongue Carcinoma 52 54 71
Malignant Neoplasm of Base of Tongue 12 32
Malignant Neoplasm of Tongue 12 71
Tongue Neoplasms 43 71
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Anterior Two-Thirds of Tongue 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue 12
Malignant Neoplasm of Ventral Tongue Surface 12
Malignant Neoplasm of Mobile Part of Tongue 12
Malignant Neoplasm of Other Sites of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Dorsum of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Neoplasm of Dorsal Tongue 12
Malignant Tumor of Posterior Tongue 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Tumor of Tongue 12
Tongue Neoplasm Malignant 12
Tongue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:8649
MeSH 43 D014062
NCIt 49 C3524 C9345
UMLS 71 C0040411 C0153349 C0153350 more

Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to oral cancer and tonsil cancer, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are GPCR Pathway and PI3K-Akt signaling pathway. The drugs Nicotine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and tonsil, and related phenotypes are cardiovascular system and immune system

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 375)
# Related Disease Score Top Affiliating Genes
1 oral cancer 30.8 TP53 MMP9 MMP2 MIR21 EGFR CDKN2A
2 tonsil cancer 30.6 TP53 NOTCH1 EGFR CDKN2A CDH1
3 papilloma 30.5 TP53 EGFR CDKN2A CDKN1A CDH1 CCND1
4 tongue squamous cell carcinoma 30.4 VEGFC TP53 NOTCH1 MMP9 MMP2 MIR21
5 keratinizing squamous cell carcinoma 30.4 TP53 EGFR CDKN2A
6 periodontitis 30.4 MMP9 MMP8 MMP2 MIR21
7 oropharynx cancer 30.4 TP53 NOTCH1 MMP8 EGFR CDKN2A CDH1
8 pulmonary emphysema 30.3 MMP9 MMP8 MMP2
9 tonsil squamous cell carcinoma 30.3 CDKN2A CCND1
10 small cell carcinoma 30.2 TP53 EGFR CDKN2A
11 b-cell lymphoma 30.2 TP53 MIR21 MALAT1 CDKN2A CDKN1A CCND1
12 mouth disease 30.2 TP53 NOTCH1 MIR491 MIR21
13 in situ carcinoma 30.1 TP53 EGFR CDKN2A CDH1 CCND1
14 rhabdomyosarcoma 30.0 TP53 EGFR CDKN2A CDKN1A CCND1
15 lynch syndrome 29.9 TP53 TERT EGFR CDKN2A CCND1
16 oral squamous cell carcinoma 29.8 VEGFC TP53 MMP9 MMP2 MIR491 MIR21
17 lymphoma, non-hodgkin, familial 29.8 TP53 NOTCH1 MIR21 CDKN2A CCND1 BMI1
18 leukemia, chronic lymphocytic 29.8 TP53 NOTCH1 MIR21 EGFR CDKN2A CCND1
19 oral cavity cancer 29.7 TP53 MMP9 MMP8 MIR491 MIR21 EGFR
20 meningioma, familial 29.6 TP53 TERT MMP9 EGFR CDKN2A CDH1
21 adenoid cystic carcinoma 29.6 TP53 NOTCH1 MMP9 MMP2 EGFR CDKN2A
22 renal cell carcinoma, nonpapillary 29.4 VEGFC TP53 MMP9 MMP2 MIR21 MALAT1
23 squamous cell carcinoma 29.1 VEGFC TP53 NOTCH1 MMP9 MMP2 MALAT1
24 leukemia, acute myeloid 29.1 TP53 TERT NOTCH1 MIR21 MALAT1 EGFR
25 larynx cancer 28.9 VEGFC TP53 TERT MMP2 MIR21 FAM3D-AS1
26 lung cancer susceptibility 3 28.9 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
27 bladder cancer 28.8 VEGFC TP53 TERT MMP9 MMP2 MIR21
28 gastric cancer 28.6 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
29 squamous cell carcinoma, head and neck 28.5 VEGFC TP53 NOTCH1 MMP9 MMP8 MMP2
30 tongue disease 28.5 TP53 PYM1 NOTCH1 MMP9 MMP8 MMP2
31 nasopharyngeal carcinoma 28.5 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
32 hepatocellular carcinoma 28.4 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
33 esophageal cancer 28.2 VEGFC TP53 TERT MMP9 MMP2 MIR21
34 cervical cancer 27.7 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
35 colorectal cancer 27.5 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
36 splenic diffuse red pulp small b-cell lymphoma 10.7 TP53 NOTCH1
37 actinic cheilitis 10.7 TP53 CDKN1A
38 invasive bladder transitional cell carcinoma 10.7 TP53 NOTCH1 CDKN1A
39 microglandular adenosis 10.6 TP53 EGFR CDH1
40 extracranial arteriovenous malformation 10.6 MMP9 MMP2
41 esophageal basaloid squamous cell carcinoma 10.6 TP53 EGFR
42 esophageal leukoplakia 10.6 TP53 CCND1
43 sarcomatoid transitional cell carcinoma 10.6 TP53 CDH1
44 carcinosarcoma 10.6 TP53 EGFR CDH1
45 serous cystadenocarcinoma 10.6 TP53 MMP2 CDKN1A
46 focal myositis 10.6 MMP9 MMP2
47 thoracic benign neoplasm 10.6 TP53 EGFR CDH1
48 breast benign neoplasm 10.6 TP53 EGFR CDH1
49 mixed cell type cancer 10.6 TP53 EGFR CDH1
50 lip cancer 10.6 TP53 MMP8 CDKN1A

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 CCND1 CDH1 CDKN1A CDKN2A EGFR MMP2
2 immune system MP:0005387 9.93 CCND1 CDH1 CDKN1A CDKN2A EGFR MMP2
3 digestive/alimentary MP:0005381 9.91 CCND1 CDH1 CDKN1A CDKN2A EGFR MMP9
4 neoplasm MP:0002006 9.7 CCND1 CDH1 CDKN1A CDKN2A EGFR MMP2
5 respiratory system MP:0005388 9.28 CCND1 CDKN1A CDKN2A EGFR MMP2 MMP9

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
tannic acid Approved Phase 4 1401-55-4
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
12 Neurotransmitter Agents Phase 4
13 Central Nervous System Stimulants Phase 4
14 Autonomic Agents Phase 4
15 Nicotinic Agonists Phase 4
16 Cholinergic Agents Phase 4
17 Anesthetics Phase 4
18 Central Nervous System Depressants Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Analgesics Phase 4
21 Hypnotics and Sedatives Phase 4
22 Anesthetics, Local Phase 4
23 Platelet Aggregation Inhibitors Phase 4
24 Anesthetics, General Phase 4
25 Anesthetics, Intravenous Phase 4
26 Anesthetics, Inhalation Phase 4
27
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
28
Histamine Approved, Investigational Phase 3 51-45-6 774
29
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
30
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
31
Promethazine Approved, Investigational Phase 3 60-87-7 4927
32
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
33
Metformin Approved Phase 3 657-24-9 14219 4091
34
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
35 Antiviral Agents Phase 3
36 Interleukin-2 Phase 3
37 Anti-Retroviral Agents Phase 3
38 Anti-HIV Agents Phase 3
39 Vaccines Phase 3
40 Psychotropic Drugs Phase 3
41 Histamine Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Antidepressive Agents Phase 3
44 Antidepressive Agents, Tricyclic Phase 3
45 Muscarinic Agonists Phase 2, Phase 3
46 Hypoglycemic Agents Phase 3
47 Antibodies, Monoclonal Phase 2, Phase 3
48
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
49
Indinavir Approved Phase 2 150378-17-9 5362440
50
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
3 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
4 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
5 Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Completed NCT00050388 Phase 3
6 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
7 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
8 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
9 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
10 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
11 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
12 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
13 Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
14 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
15 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
16 A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
17 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
18 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Completed NCT02849379 Phase 1, Phase 2
20 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Completed NCT03008330 Phase 1, Phase 2
21 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
22 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
23 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
24 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
25 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
26 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
27 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
28 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
29 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
30 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
31 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
32 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
33 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
34 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
35 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
36 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
37 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
38 Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection Completed NCT00875849 Phase 2 cisplatin
39 Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
40 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
41 A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers Completed NCT00423930 Phase 2 cisplatin
42 A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma Completed NCT00851877 Phase 1, Phase 2 Cisplatin;Nab-Paclitaxel
43 Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
44 A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
45 Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
46 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
47 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
48 A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy Terminated NCT03161548 Phase 2 Induction chemotherapy
49 DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Terminated NCT01313390 Phase 1, Phase 2 docetaxel;everolimus
50 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

40
Tongue, Lymph Node, Tonsil, Lung, Breast, Brain, Bone

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 2017)
# Title Authors PMID Year
1
Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. 54 61
19331169 2009
2
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. 54 61
18253113 2008
3
Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. 54 61
17611661 2007
4
NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. 54 61
17005413 2006
5
Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. 54 61
16767431 2006
6
Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. 54 61
16331606 2006
7
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells]. 54 61
16285558 2005
8
The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. 54 61
15289890 2004
9
Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. 54 61
14730689 2004
10
Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. 54 61
14977084 2004
11
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. 54 61
12454097 2002
12
Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. 54 61
11900224 2002
13
A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. 54 61
11206273 2001
14
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. 54 61
11315101 2000
15
p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. 54 61
10645402 1999
16
Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study. 54 61
8736172 1996
17
Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. 54 61
7829949 1994
18
Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. 54 61
8181582 1994
19
Association between pathological invasion patterns and late lymph node metastases in patients with surgically treated clinical No early oral tongue carcinoma. 61
31647162 2020
20
A descriptive study highlighting the differences in the treatment protocol for oral tongue cancer in Sweden and Finland. 61
31852347 2020
21
An examination of the cutoff value of the depth of invasion for prophylactic neck dissection in stage I/II tongue cancer. 61
32022616 2020
22
A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. 61
31733108 2020
23
Incidental finding of tongue cancer in a PET scan: A fusion of anatomic and metabolic imaging. 61
31351902 2020
24
Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. 61
31650410 2020
25
Acceptable fetal dose using flattening filter-free volumetric arc therapy (FFF VMAT) in postoperative chemoradiotherapy of tongue cancer during pregnancy. 61
31709307 2020
26
Rehabilitation of speech disorders following glossectomy, based on ultrasound visual illustration and feedback. 61
31992079 2020
27
Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells. 61
31738907 2020
28
Circulating Tumor DNA in Saliva in an Orthotopic Head and Neck Cancer Mouse Model. 61
31892567 2020
29
A new and 23 known cardenolide glycosides from Thevetia neriifolia seeds and their cytotoxic activities against human oral carcinoma cell lines. 61
31967486 2020
30
Assessment of Chronological Volume Changes in Radial Forearm Free Flaps for Tongue Cancer. 61
31905363 2020
31
Mortality due to oral and oropharyngeal cancer in Uruguay from 1997 to 2014. 61
31800875 2020
32
Global patterns and trends in cancers of the lip, tongue and mouth. 61
31986342 2020
33
Inhibitory effect of the Notch pathway-inhibitor DAPT on invasion and metastasis of tongue cancer via lncRNA-KAT14 regulation. 61
31957832 2020
34
LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis. 61
31957833 2020
35
Proline-Dependent Induction of Apoptosis in Oral Squamous Cell Carcinoma (OSCC)-The Effect of Celecoxib. 61
31935820 2020
36
Anatomically-based transoral surgical approach to early-stage oral tongue squamous cell carcinoma. 61
32003091 2020
37
Progress in the study of long noncoding RNA in tongue squamous cell carcinoma. 61
31611036 2020
38
Elevated matrix metalloproteinase 7 expression promotes the proliferation, motility and metastasis of tongue squamous cell carcinoma. 61
31937294 2020
39
Histological characteristics of early-stage oral tongue cancer in young versus older patients: A multicenter matched-pair analysis. 61
31994277 2020
40
Elective Neck Dissection, but Not Adjuvant Radiation Therapy, Improves Survival in Stage I and II Oral Tongue Cancer with Depth of Invasion >4 mm. 61
31828000 2019
41
Prediction of postoperative lower respiratory tract infections in tongue cancer patients based on pretreatment swallowing function. 61
31886583 2019
42
A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer. 61
31969916 2019
43
Human papillomavirus type 18 oncoproteins exert their oncogenicity in esophageal and tongue squamous cell carcinoma cell lines distinctly. 61
31830929 2019
44
The preservation and application of the submandibular gland in oral squamous cell carcinoma (STROBE). 61
31876743 2019
45
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines. 61
31788102 2019
46
Comparison of supervised machine learning classification techniques in prediction of locoregional recurrences in early oral tongue cancer. 61
31923822 2019
47
[Chimeric perforator flap based on the descending branch of lateral circumflex femoral artery for tongue reconstruction after advanced tongue cancer resection]. 61
31887816 2019
48
Epigenomic dysregulation-mediated alterations of key biological pathways and tumor immune evasion are hallmarks of gingivo-buccal oral cancer. 61
31796082 2019
49
Tongue cancer: A discrete oral cavity subsite. 61
31272801 2019
50
Anti-tumor properties of silver. 61
31828988 2019

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 VEGFC TP53 NOTCH1 MMP9 MMP8 MMP2
2
Show member pathways
12.92 VEGFC TP53 TERT NOTCH1 EGFR CDKN1A
3
Show member pathways
12.8 TP53 MMP9 EGFR CDKN2A CDKN1A CDH1
4
Show member pathways
12.7 TP53 TERT NOTCH1 EGFR CDKN2A CDKN1A
5
Show member pathways
12.57 TP53 NOTCH1 MMP9 MMP2 EGFR CDKN2A
6 12.42 VEGFC TP53 TERT NOTCH1 MMP9 MMP2
7
Show member pathways
12.37 TP53 CDKN2A CDKN1A CCND1
8
Show member pathways
12.35 TP53 CDKN2A CDKN1A CCND1
9 12.33 TP53 CDKN2A CDKN1A CDH1 CCND1
10 12.3 TP53 NOTCH1 MMP9 MIR21 EGFR CDKN2A
11 12.29 TP53 CDKN2A CDKN1A CCND1
12 12.29 TP53 TERT CDKN2A CDKN1A CCND1
13 12.26 TP53 MMP9 MMP2 MIR21 EGFR CDKN1A
14 12.24 TP53 MMP9 CDKN1A BMI1
15 12.16 TP53 CDKN2A CDKN1A CCND1
16 12.14 TP53 EGFR CDH1 CCND1
17 12.13 TP53 MMP9 MMP2 EGFR CDKN1A CDH1
18
Show member pathways
12.1 MMP2 EGFR CDKN1A CCND1
19 12.06 TP53 TERT CDKN1A CCND1
20 12.05 TP53 MMP2 EGFR CDKN1A
21 12 TP53 MMP9 EGFR CCND1
22 11.96 TP53 CDKN2A CDKN1A CCND1
23 11.95 TP53 MMP9 MMP2 CDKN1A CCND1
24 11.92 TP53 CDKN2A CDKN1A BMI1
25 11.92 TP53 EGFR CDKN2A CDKN1A CCND1
26 11.84 EGFR CDKN1A CCND1
27 11.83 TP53 CDKN1A CCND1
28 11.81 VEGFC NOTCH1 MMP9 MMP2
29 11.75 TERT MMP9 MMP2 CDH1 CCND1
30 11.74 TP53 CDKN2A CDKN1A
31 11.73 TP53 TERT MMP9 BMI1
32 11.7 TP53 MMP2 CDKN2A CDKN1A
33 11.69 TERT EGFR CCND1
34 11.69 MMP9 MMP2 EGFR
35 11.67 MMP9 MMP2 EGFR
36
Show member pathways
11.65 MMP9 MMP2 CCND1
37 11.65 TERT MMP9 MMP2
38 11.63 MMP9 MMP2 EGFR
39
Show member pathways
11.6 MMP9 MMP2 EGFR CCND1
40 11.57 VEGFC TP53 CDKN2A
41 11.54 TP53 CDKN1A CCND1
42 11.53 TP53 CDKN1A CCND1
43 11.46 TP53 CDKN1A CCND1
44 11.44 TP53 MMP2 EGFR CDKN2A CDKN1A CCND1
45 11.33 MMP9 MMP2 CCND1
46 11.29 TP53 CDKN1A CCND1
47
Show member pathways
11.09 TP53 CDKN2A CDKN1A
48 11.09 TP53 MMP9 MMP2 EGFR CDKN2A CDKN1A
49 10.78 TP53 CDKN1A
50
Show member pathways
10.59 TP53 CDKN1A

GO Terms for Tongue Cancer

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 TP53 NOTCH1 MMP8 MIR21 CDKN2A
2 negative regulation of cell proliferation GO:0008285 10.02 TP53 NOTCH1 MIR21 CDKN2A CDKN1A
3 positive regulation of apoptotic process GO:0043065 9.98 TP53 NOTCH1 MMP9 MIR21 CDKN2A
4 negative regulation of apoptotic process GO:0043066 9.97 TP53 TERT MMP9 MIR21 EGFR CDKN1A
5 positive regulation of cell migration GO:0030335 9.96 NOTCH1 MMP9 MIR21 EGFR
6 extracellular matrix organization GO:0030198 9.95 MMP9 MMP8 MMP2 CDH1
7 response to drug GO:0042493 9.91 VEGFC TP53 CDKN1A CDH1 CCND1
8 cytokine-mediated signaling pathway GO:0019221 9.88 TP53 MMP9 MMP2 CDKN1A CCND1
9 liver development GO:0001889 9.84 NOTCH1 EGFR CCND1
10 cell cycle arrest GO:0007050 9.83 TP53 NOTCH1 CDKN2A CDKN1A
11 Ras protein signal transduction GO:0007265 9.81 TP53 CDKN2A CDKN1A
12 extracellular matrix disassembly GO:0022617 9.79 MMP9 MMP8 MMP2
13 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 MIR21 CDKN2A CDKN1A
14 positive regulation of fibroblast proliferation GO:0048146 9.77 EGFR CDKN1A BMI1
15 positive regulation of protein phosphorylation GO:0001934 9.77 VEGFC MMP9 MIR21 EGFR CCND1
16 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.74 TERT EGFR CCND1
17 animal organ regeneration GO:0031100 9.73 NOTCH1 CDKN1A CCND1
18 collagen catabolic process GO:0030574 9.72 MMP9 MMP8 MMP2
19 embryo implantation GO:0007566 9.71 MMP9 MMP2 MIR21
20 negative regulation of glial cell proliferation GO:0060253 9.65 TERT NOTCH1
21 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
22 regulation of neuroinflammatory response GO:0150077 9.64 MMP9 MMP8
23 somatic stem cell division GO:0048103 9.64 NOTCH1 CDKN2A
24 negative regulation of gene expression GO:0010629 9.63 TP53 TERT NOTCH1 MMP8 MIR21 CDKN1A
25 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
26 positive regulation of epithelial cell proliferation GO:0050679 9.62 VEGFC NOTCH1 EGFR CCND1
27 endodermal cell differentiation GO:0035987 9.61 MMP9 MMP8 MMP2
28 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.6 TP53 NOTCH1
29 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
30 response to X-ray GO:0010165 9.58 TP53 CDKN1A CCND1
31 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 TERT MMP9 MMP2 MIR21
32 response to UV-A GO:0070141 9.46 EGFR CCND1
33 cellular response to reactive oxygen species GO:0034614 9.26 TP53 MMP9 MMP2 EGFR
34 replicative senescence GO:0090399 8.92 TP53 TERT CDKN2A CDKN1A

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 TP53 EGFR CDKN2A CDKN1A CCND1
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN2A CDKN1A

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....